Sulfur Containing Patents (Class 536/54)
-
Publication number: 20120309707Abstract: The present invention relates to the use of a series of sulphated disaccharides for the preparation of a medicament for the treatment or prevention of a neurodegenerative and/or neurovascular disease, of a traumatic brain injury or of a traumatic spinal cord injury. The present invention also relates to the use of said sulphated disaccharides for the preparation of a neuroprotective medicament or of an antioxidant medicament. The neurodegenerative and/or neurovascular diseases are preferably: Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis and stroke.Type: ApplicationFiled: December 22, 2010Publication date: December 6, 2012Applicants: UNIVERSIDAD AUTONOMA DE MADRID, BIOIBERICA, S.A.Inventors: Josep Verges Milano, Antonio Garcia Garcia, Ramon Ruhi Roura, Eulalia Montell Bonaventura, Manuela Garcia Lopez, Carlos Raul Alaez Verson, Josep Escaich Ferrer, Javier Egea Maiquez, Pilar Negredo Madrigal, Silvia Lorrio Gonzalez
-
Publication number: 20120309955Abstract: Certain zwitterionic polysaccharides, including those naturally expressed by commensal B. fragilis in the gut, interact with cells of the immune system and affect the TH1/TH2 balance so as to promote health. Nutritional formulas and nutritional supplements containing isolated preparations of such zwitterionic polysaccharides, and methods for preparing the nutritional formulas and supplements, are provided. Also provided is a method of promoting immune system maturation in an infant involving enteral administration of a nutritional formula or nutritional supplement of the invention.Type: ApplicationFiled: June 11, 2012Publication date: December 6, 2012Applicant: The Brigham and Women's Hospital, Inc.Inventors: Dennis L. Kasper, Sarkis M. Mazmanian
-
Publication number: 20120276108Abstract: The present invention relates to compounds and methods which may be useful as inhibitors of glycolysis, inhibitors of protein glycosylation, anti-virals, and down-regulators of insulin receptor and IGF-1 receptor for the treatment or prevention of inflammatory dermatological diseases or proliferative dermatological diseases.Type: ApplicationFiled: January 11, 2012Publication date: November 1, 2012Applicant: INTERTECH BIOInventor: Waldemar Priebe
-
Publication number: 20120264702Abstract: The present invention relates to methods and compositions for the synthesis, production, and use of pro-drug propofol analogs. This invention relates to a method for the production of a broad group of glycosylated propofol carbohydrate derivatives.Type: ApplicationFiled: April 9, 2012Publication date: October 18, 2012Inventors: Brian Shull, John Baldwin, Ramesh Gopalaswamy, Zishan Haroon
-
Patent number: 8288515Abstract: Processes for the synthesis of the Factor Xa anticoagulent Fondaparinux, and related compounds are described. Also described are protected pentasaccharide intermediates as well as efficient and scalable processes for the industrial scale production of Fondaparinux sodium by conversion of the protected pentasaccharide intermediates via a sequence of deprotection and sulfonation reactions.Type: GrantFiled: July 30, 2010Date of Patent: October 16, 2012Assignee: Reliable Biopharmaceutical CorporationInventors: Sourena Nadji, James T. Smoot, Joseph A. Vanartsdalen
-
Publication number: 20120253029Abstract: A new method is described for the oversulfation of epiK5-N-sulfate to obtain an epiK5-amine-O-oversulfate with very high sulfation degree which, by subsequent N-sulfation, provides new epiK5-N,O-oversulfate-derivatives with a sulfation degree of at least 4, basically free of activity on the coagulation parameters and useful in the cosmetic or pharmaceutical field. Also described are new low molecular weight epiK5-N-sulfates useful as intermediates in the preparation of the corresponding LMW-epiK5-N,O-oversulfate-derivatives.Type: ApplicationFiled: May 7, 2012Publication date: October 4, 2012Inventors: Pasqua Anna ORESTE, Giorgio Zoppetti
-
Publication number: 20120208993Abstract: Preparation and use of synthetic trisaccharides useful for the preparation of synthetic heparinoids.Type: ApplicationFiled: December 14, 2011Publication date: August 16, 2012Applicant: Alchemia LimitedInventors: Joachim SEIFERT, Latika SINGH, Tracie Elizabeth RAMSDALE, Michael Leo WEST, Nicholas Barry DRINNAN
-
FGF RECEPTOR-ACTIVATING N-SULFATE OLIGOSACCHARIDES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF
Publication number: 20120202769Abstract: The invention relates to FGF receptor-activating N-sulfate oligosaccharides having Formula (I), wherein R1, R4, R6, and R8 are —OSO3? or hydroxyl groups, R2 is an —O-alkyl group or a monosaccharide having Formula (II), R3 is a disaccharide having Formula (III), R5 is a disaccharide having Formula (IV), R7 is a hydroxyl group or a disaccharide having Formula (VI), and R9 is a hydroxyl or —O-alkyl group or a disaccharide having Formula (VII), where R10- is an —O-alkyl group. The invention further relates to the preparation of said oligosaccharides and to the therapeutic use thereof.Type: ApplicationFiled: February 9, 2012Publication date: August 9, 2012Applicant: SANOFIInventors: Philippe DUCHAUSSOY, Pierre FONS, Alexandre FROIDBISE -
Publication number: 20120122805Abstract: The invention disclosed in this document is related to the field of pesticides and their use in controlling pests. A compound having the following structure is disclosed.Type: ApplicationFiled: January 25, 2012Publication date: May 17, 2012Applicant: DOW AGROSCIENCES LLCInventors: Gary D. Crouse, Thomas C. Sparks, CaSandra Lee McLeod, David A. Demeter, Kristy Bryan, Annette V. Brown, William H. Dent, III, Denise P. Cudworth, Jaime S. Nugent, Ricky Hunter, Jack G. Samaritoni
-
Publication number: 20110319608Abstract: The present invention relates to a process for preparing a mixed salt of glucosamine sulfate and an alkali metal chloride. The process comprises the consecutive steps of: a) suspending glucosamine hydrochloride in a non-aqueous solvent, b) adding thereto a solution of a basic alkali metal salt in water, and c) adding thereto a solution of an alkali metal hydrogen sulfate in water whereby the mixed salt is obtained.Type: ApplicationFiled: November 5, 2009Publication date: December 29, 2011Inventors: Mahesh Devdhar, Trupti Darge, Rahul Jadhav
-
Patent number: 8067196Abstract: Disclosed are methods of 6-O-sulfating glucosaminyl N-acetylglucosamine residues (GlcNAc) in a polysaccharide preparation and methods of converting anticoagulant-inactive heparan sulfate to anticoagulant-active heparan sulfate and substantially pure polysaccharide preparations may by such methods. Also disclosed is a mutant CHO cell which hyper-produces anticoagulant-active heparan sulfate. Methods for elucidating the sequence of activity of enzymes in a biosynthetic pathway are provided.Type: GrantFiled: March 28, 2002Date of Patent: November 29, 2011Assignee: Massachusetts Institute of TechnologyInventors: Robert D. Rosenberg, Lijuan Zhang, David L. Beeler
-
Publication number: 20110280914Abstract: Described herein are composites useful in tissue and organ engineering. In one aspect, the composite comprises the reaction product between a macromolecule comprising at least one thiol group and a gold nanoparticle. The thiolated macro-molecule crosslinks with the gold nanoparticle to produce a composite that is useful in anchoring cells. The composites can be used to form multi-layer 3-D structures, where the cells in each layer can aggregate and fuse with one another to form tissues and organs.Type: ApplicationFiled: December 17, 2009Publication date: November 17, 2011Applicant: University of Utah Research FoundationInventors: Glenn D. Prestwich, Aleksander Skardel, Jianxing Zhang
-
Publication number: 20110245196Abstract: The invention relates to novel compounds that have utility as inhibitors of heparan sulfate-binding proteins; compositions comprising the compounds, and use of the compounds and compositions thereof for the antiangiogenic, antimetastatic, anti-inflammatory, antimicrobial, anticoagulant and/or antithrombotic treatment of a mammalian subject.Type: ApplicationFiled: October 16, 2008Publication date: October 6, 2011Inventors: Vito Ferro, Karoli Tomislav, Liu Ligong, Handley Paul Newton, Johnstone Kenneth David, Norbert Wimmer, Hammond Edward Timothy
-
Publication number: 20110237527Abstract: The present invention relates to compounds which are inhibitors of sodium dependent glucose co-transporter-2 (SGLT-2). These compounds are used in the treatment of various disorders, including diabetes, impaired glucose tolerance, insulin resistance, retinopathy, nephropathy, neuropathy, cataracts, hyperglycemia, hyperinsulinemia, hyperchlolesterolemia, elevated blood level of free fatty acids or glycerol, hyperlipidemia, hypertriglyceridemia, obesity, wound healing, tissue ischemia, atherosclerosis, and hypertension. These compounds and compositions are also useful for treating and preventing kidney stones, hyperuricemia, gout, and hyponatremia. Methods of making these compounds are also described in the present invention.Type: ApplicationFiled: March 21, 2011Publication date: September 29, 2011Applicant: ALBANY MOLECULAR RESEARCH, INC.Inventors: Shuang LIU, Cheng GUO, Min HU, Douglas B. KITCHEN, Peter R. GUZZO, Russell DEORAZIO
-
Publication number: 20110230652Abstract: This invention provides compounds represented by the structure of the general formula (A): wherein L is a lipid or a phospholipid, Z is either nothing, ethanolamine, serine, inositol, choline, or glycerol, Y is either nothing or a spacer group ranging in length from 2 to 30 atoms, X is a physiologically acceptable monomer, dimer, oligomer, or polymer, wherein X is a glycosaminoglycan; and n is a number from 1 to 1000, wherein any bond between L, Z, Y and X is either an amide or an esteric bond.Type: ApplicationFiled: February 22, 2011Publication date: September 22, 2011Inventor: Saul YEDGAR
-
Publication number: 20110230403Abstract: The present invention relates to compounds of formula I and pharmaceutically acceptable salts, to formulations and uses of the compounds of formula (I) in the treatment of metabolic disorders.Type: ApplicationFiled: September 17, 2009Publication date: September 22, 2011Applicant: NOVARTIS AGInventors: P. Venkata Palle, Dumbala Srinivas Reddy, Suresh Eknath Kurhade, Debnath Bhuniya
-
Patent number: 8012942Abstract: Provided are thieno[3,4-d]pyrimidin-7-yl and furo[3,4-d]pyrimidin-7-yl ribosides, riboside phosphates and prodrugs thereof as well as intermediates and methods of preparation. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections.Type: GrantFiled: February 9, 2010Date of Patent: September 6, 2011Assignee: Gilead Sciences, Inc.Inventors: Thomas Butler, Aesop Cho, Choung U. Kim, Jie Xu
-
Publication number: 20110190486Abstract: The invention concerns the production of quinoline compounds containing sulfonic acid groups, the said quinoline compounds and their conversion into dyes containing sulfonic acid groups. The dyes according to the invention are used especially to label analytes, for example to label biomolecules.Type: ApplicationFiled: March 25, 2011Publication date: August 4, 2011Applicant: ATTO-TEC GMBHInventors: Alexander Zilles, Jutta Arden-Jacob, Karl-Heinz Drexhage, Norbert Uwe Kemnitzer, Monika Hamers-Schneider
-
Publication number: 20110130553Abstract: Novel synthesis routes for preparation of thiodigalactosides and intermediates are presented. The method includes the use of a 3-azido-galactosyl thiouronium salt derivative, which is activated to the corresponding thiol in situ, which in turn is directly reacted with a 3-azido-galactosyl bromide resulting in the 3,3?-di-azido-thio-di-galactoside before the thiol has a chance to reduce the azido 10 group. Hence, in situ formation of the 3-azido-galactosyl thiol from the thiouronium salt is essential in the synthesis procedure, because any other method that generate the thiol separately results in extensive unwanted azide reduction.Type: ApplicationFiled: May 18, 2009Publication date: June 2, 2011Inventor: Ulf Nilsson
-
Publication number: 20110098455Abstract: A process for producing a polysaccharide sponge comprises the steps of (A) freezing a photoreactive polysaccharide solution, and (B) irradiating the frozen photoreactive polysaccharide solution with light to crosslink the photoreactive polysaccharide, thereby obtaining the polysaccharide sponge. The process includes simplified steps requiring no removal of solvent, and has such an advantage that impurities are easily removed therefrom.Type: ApplicationFiled: December 29, 2010Publication date: April 28, 2011Applicant: SEIKAGAKU CORPORATIONInventor: Tomoya Sato
-
Publication number: 20100322958Abstract: Modified capsular saccharides comprising a blocking group at a hydroxyl group position on at least one of the monosaccharide units of the corresponding native capsular saccharide, wherein the blocking group is of the formula (Ia) or (Ib): —OX—Y (Ia) or —O—R1 (Ib) wherein X is C(O), S(O) or SO2; Y is NR1R2 or R3; R1 is C1-6 alkyl substituted with 1, 2 or 3 groups independently selected from hydroxyl, sulphydryl and amine; R2 is H or C1-6 alkyl; and R3 is C1-6 alkyl; processes for modifying a capsular saccharide with the blocking groups; saccharide-protein conjugates comprising the modified capsular saccharide; processes for making the saccharide-protein conjugates, pharmaceutical compositions comprising the modified capsular saccharides and/or saccharide-protein conjugates; and methods and uses of the same.Type: ApplicationFiled: January 11, 2008Publication date: December 23, 2010Inventors: Angela Bardotti, Alessandro Pianigiani, Francesco Berti, Paolo Costantino
-
Publication number: 20100317617Abstract: A silver nanocomposite, a formation method for forming the silver nanocomposite, and an application method utilizing the silver nanocomposite. The silver nanocomposite includes a silver nanoparticle conjugated to a glycosaminoglycan (GAG) or glucose. The formation method includes chemically reacting silver nitrate with a reducing agent to form a silver nanoparticle conjugated to the reducing agent of a GAG or glucose. The application method may include topically applying the silver nanocomposite to a wound or burn as an anti-microbial with respect to an antibiotic-resistant genotype in the wound or burn, wherein the silver nanocomposite topically applied includes the silver nanoparticle conjugated to the GAG of 2,6-diaminopyridinyl heparin (DAPHP) or hyaluronan (HA). The application method may include applying the silver nanocomposite as a coating to plastic, a catheter, or a surgical tool, wherein the silver nanocomposite applied as the coating includes the silver nanoparticle conjugated to the GAG of DAPHP.Type: ApplicationFiled: June 9, 2010Publication date: December 16, 2010Applicant: VASCULAR VISION PHARMACEUTICAL CO.Inventors: Shaker A. Mousa, Robert Linhardt
-
Patent number: 7812151Abstract: Novel depolymerized-LMWepiK5-N,O-sulfates obtainable starting from a LMW-epiK5-N-sulfate prepared by nitrous depolymerization of an epiK5-N-sulfate or by C5-epimerization of a LMW-K5-N-sulfate obtained by nitrous depolymerization of a K5-N-sulfate. A process consists of submitting the starting depolymerized-LMW-epiK5-N-sulfate to four steps: a O-oversulfation, a partila O-desulfation, a 6-O-sulfation and a N-sulfation. The new depolymerized-LMWepiK5-N,O-sulfates present a di- or trisulfated 2,5-anhydromannitol unit at the reducing end of the majority of its chains, have a content of iduronic acid of 40-60%, a sulfation degree of from 2.3 to 2.9 and a mean molecular weight of from about 1,500 to about 12,000. They exhibit a good antithrombotic activity with a low pro-hemorrhagic risk.Type: GrantFiled: December 15, 2004Date of Patent: October 12, 2010Assignee: Glycores 2000 S.R.L.Inventors: Pasqua Anna Oreste, Giorgio Zoppetti
-
Patent number: 7812142Abstract: The present invention relates to pentose and pentose derivatives that are effective at increasing glucose transport in a non-insulin dependent manner, and to uses thereof for a) treating and/or preventing hyperglycemia; b) treating and/or preventing the complications of hyperglycemia; c) treating diabetes; d) increasing the rate of cellular glucose transport; e) increasing the rate of cellular glucose uptake; f) improving the ability of a subject to metabolize glucose; g) treating daily blood glucose fluctuations; h) reducing blood sugar levels; i) reducing the dosage of anti-diabetic medication needed for treatment of diabetes. The present invention further provides novel pentose derivatives having beneficial properties in terms of pharmacokinetics, to pharmaceutical compositions comprising these novel compounds and uses thereof.Type: GrantFiled: April 19, 2005Date of Patent: October 12, 2010Assignees: Yissum Research Development Company of the Hebrew University of Jerusalem, Hadasit Medical Research Services and Development Ltd.Inventors: Shlomo Sasson, Erol Cerasi, Arie Gruzman, Joshua Katzhendler
-
Publication number: 20100249061Abstract: The invention relates to oligosaccharides, the preparation method and use thereof, and pharmaceutical compositions containing same. More specifically, the invention relates to oligosaccharides which can be used for the treatment of cancer and, in particular, to prevent and inhibit the formation of metastases. The inventive oligosaccharides can be used, for example, during early breast, lung, prostate, colon or pancreatic cancer. The oligosaccharides can be administered subcutaneously, orally or intravenously. Moreover, said oligosaccharides can be used alone or together with other anticancer agents, e.g. cytotoxics such as docetaxel or paclitaxel.Type: ApplicationFiled: January 21, 2010Publication date: September 30, 2010Applicant: Aventis Pharma S.A.Inventors: Christian VISKOV, Pierre MOURIER
-
Publication number: 20100240601Abstract: A coordination complex having a physiologically acceptable pKa includes a metal and a biologically active agent. The pKa of the coordination complex is less than the pKa of the biologically active agent. A pharmaceutical solution for treating a patient includes a coordination complex and water, wherein the coordination complex is at least partially soluble in the water at physiological pH and in a therapeutically efficacious concentration. A method for treating a patient includes administering a pharmaceutical solution including a coordination complex and water to a patient in need of a biologically active agent.Type: ApplicationFiled: May 26, 2010Publication date: September 23, 2010Inventors: Thomas Piccariello, John D. Price, Robert A. Oberlender, Michaela E. Mulhare, Mary C. Spencer, Scott B Palmer
-
Publication number: 20100227836Abstract: Materials and methods for local delivery of a glucosamine are provided to facilitate bone and cartilage growth.Type: ApplicationFiled: September 30, 2009Publication date: September 9, 2010Applicant: THE JOHNS HOPKINS UNIVERSITYInventors: JENNIFER H. ELISSEEFF, SHYNI VARGHESE, JEANNINE COBURN, MATTHEW GIBSON, ZAYNA NAHAS, ZHAOYANG YE
-
Publication number: 20100203015Abstract: Provided are thieno[3,4-d]pyrimidin-7-yl and furo[3,4-d]pyrimidin-7-yl ribosides, riboside phosphates and prodrugs thereof as well as intermediates and methods of preparation. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections.Type: ApplicationFiled: February 9, 2010Publication date: August 12, 2010Applicant: Gilead Sciences, Inc.Inventors: Thomas Butler, Aesop Cho, Choung U. Kim, Jie Xu
-
Publication number: 20100197030Abstract: The present invention relates to fluorescent dyes in general. The present invention provides a wide range of fluorescent dyes and kits containing the same, which are applicable for labeling a variety of biomolecules, cells and microorganisms. The present invention also provides various methods of using the fluorescent dyes for research and development, forensic identification, environmental studies, diagnosis, prognosis, and/or treatment of disease conditions.Type: ApplicationFiled: February 3, 2010Publication date: August 5, 2010Applicant: Biotium, Inc.Inventors: Fei Mao, Wai-Yee Leung, Ching-Ying Cheung
-
Publication number: 20100179314Abstract: The present invention provides a novel and highly stereoselective process for preparing gemcitabine, which is suitable for industrial production, wherein, it includes the following reactions. Additionally, the invention discloses the key intermediates. The definition for the groups of G1, G2, G3, G4, and G5 are described in the specification.Type: ApplicationFiled: September 7, 2007Publication date: July 15, 2010Applicant: NANJING CAVENDISH BIO-ENGINEERING TECHNOLOGY CO.,Inventors: Yongxiang Xu, Hao Yang, Wen Hou
-
Publication number: 20100167991Abstract: The invention relates to a polysaccharide comprising carboxyl functional groups, one at least of which is substituted by a derivative of a hydrophobic alcohol. The invention also relates to a pharmaceutical composition comprising one of the polysaccharides according to the invention and at least one active principle. It also relates to a pharmaceutical composition, wherein the active principle is chosen from the group consisting of proteins, glycoproteins, peptides and nonpeptide therapeutic molecules. The invention also relates to the use of the functionalized polysaccharides according to the invention in the preparation of pharmaceutical compositions as described above.Type: ApplicationFiled: October 6, 2009Publication date: July 1, 2010Applicant: ADOCIAInventors: Remi Soula, Olivier Soula, Gerard Soula, Richard Charvet
-
Publication number: 20100143300Abstract: The invention provides methods for treating hepatitis C viral infections and related viral infections, as well as compounds and compositions that are useful for treating such infections.Type: ApplicationFiled: March 6, 2009Publication date: June 10, 2010Inventors: Yarlagadda S. Babu, Pooran Chand, Minwan Wu, Pravin L. Kotian, V. Satish Kumar, Tsu-Hsing Lin, Yahya El-Kattan, Ajit K. Ghosh
-
Patent number: 7700763Abstract: The present invention relates to novel compounds, the use of said compounds as a medicament as well as for the manufacture of a medicament for treatment of disorders relating to the binding of galectin to receptors in a mammal. Said galectin is preferably a galectin-3.Type: GrantFiled: November 20, 2006Date of Patent: April 20, 2010Assignee: Forskarpatent I Syd ABInventors: Hakon Leffler, Bader Abdalraheem Bader Salameh, Ulf Nilsson
-
Patent number: 7687619Abstract: Room temperature stable, non-gelling polysaccharide solutions such as agaroses, dextrans and cyclodextrans are made by the present invention. It has been found that by incorporating certain gel-inhibiting additives into an aqueous polysaccharide solution, the gel point is reduced or eliminated and the solution remains liquid at room temperature indefinitely. Additives that have been found to work include salts, such as lithium chloride and zinc chloride and bases, such as sodium hydroxide and lithium hydroxide. Mixtures of said salts and said bases can also be used with the same desired results. The composition of these solutions of the present idea can be further modified to include other additives, such as organic co-solvents or non-solvents, pH modifiers, surfactants or other polymers to customize the properties of the solution to improve the processability for the desired application and to form structures such as films, beads and coated porous substrates.Type: GrantFiled: February 3, 2005Date of Patent: March 30, 2010Assignee: Millipore CorporationInventors: Wilson Moya, Neil P. Soice
-
Publication number: 20100048483Abstract: The present invention relates to polymeric derivatives, which can be conjugated to an amino-containing drug to improve its in vivo properties. The polymeric derivative can subsequently be released to yield the drug in its native form. Methods of preparing and using these polymeric derivatives and drug conjugates are described.Type: ApplicationFiled: August 21, 2009Publication date: February 25, 2010Applicants: BAXTER HEALTHCARE S.A., BAXTER INTERNATIONAL INC.Inventors: Guohan Yang, Ton T. Hai, Bennett Melnick, Paul Sanders, Cong Jiang, Catherine Quinn, Jie Li, Arounaguiry Ambroise, Larry R. Brown
-
Patent number: 7666845Abstract: The invention is directed to compounds of the formula (I) described herein, a pharmaceutically acceptable salt thereof, or a prodrug thereof, and pharmaceutical compositions and methods of treatment.Type: GrantFiled: December 3, 2007Date of Patent: February 23, 2010Assignee: Janssen Pharmaceutica N.V.Inventors: Kevin L. Cook, Heng-Keang Lim, Frank J. Villani, Lorraine Scott, Christian Andrew Baumann
-
Publication number: 20100008860Abstract: The invention concerns color-marked oligosaccharides or polysaccharides, procedures for the synthesis of these color-marked oligosaccharides or polysaccharides and their use in the determination of kidney function.Type: ApplicationFiled: January 23, 2008Publication date: January 14, 2010Applicant: UNIVERSITAT HEIDELBERGInventors: Jorg Kowalczyk, Thomas Rose, Stephan Hausmanns, Thomas Walter, Wolfgang Wach, Norbert Gretz, Maliha Sadick, Daniel Schock
-
Publication number: 20090326215Abstract: Glucopyranosyl-substituted benzene derivatives of general formula I where the groups R1 to R6 as well as R7a, R7b, R7c are defined herein and the tautomers, the stereoisomers thereof, the mixtures thereof and the salts thereof. The compounds according to the invention are suitable for the treatment of metabolic disorders.Type: ApplicationFiled: August 21, 2009Publication date: December 31, 2009Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBHInventors: Matthias ECKHARDT, Peter EICKELMANN, Frank HIMMELSBACH, Edward Leon BARSOUMIAN, Leo THOMAS
-
Publication number: 20090317427Abstract: Certain zwitterionic polysaccharides, including those naturally expressed by commensal B. fragilis in the gut, interact with cells of the immune system and affect the TH1/TH2 balance so as to promote health. Nutritional formulas and nutritional supplements containing isolated preparations of such zwitterionic polysaccharides, and methods for preparing the nutritional formulas and supplements, are provided. Also provided is a method of promoting immune system maturation in an infant involving enteral administration of a nutritional formula or nutritional supplement of the invention.Type: ApplicationFiled: February 5, 2007Publication date: December 24, 2009Applicant: The Brigham and Women's Hospital, Inc. Corporate Sponsored Research and LicensingInventors: Dennis L. Kasper, Sarkis K. Mazmanian
-
Patent number: 7622575Abstract: The present invention is directed to methods of using glucan compositions, comprising water insoluble microparticulate glucans, in the treatment of connective tissue injuries. The water insoluble microparticulate glucans used in the compositions comprise branched ?-(1,3)(1,6) glucan. The glucan compositions used in the present invention are essentially free of unbranched ?-(1,3)(1,6) glucan and non-glucan components.Type: GrantFiled: August 4, 2006Date of Patent: November 24, 2009Assignee: Novogen Research Pty. Ltd.Inventor: Graham Edmund Kelly
-
Publication number: 20090264525Abstract: The present invention relates to fatty acid esters of polyols or sulfonated fatty acid esters or sulfonated fatty acid amides containing at least one group Y, where Y stands for CF3—(CH2)a—O—, SF5—, CF3—(CH2)a—S—, CF3CF2S—, [CF3—(CH2)a]2N— or [CF3—(CH2)a]NH—, where a stands for an integer selected from the range from 0 to 5, or formula (I), where Rf stands for CF3—(CH2)r—, CF3—(CH2)r—O—, CF3—(CH2)r—S—, CF3CF2—S—, SF5—(CH2)t— or [CF3—(CH2)r]2N—, [CF3—(CH2)r]NH— or (CF3)2N—(CH2)r—, B stands for a single bond, O, NH, NR, CH2, C(O)—O, C(O), S, CH2—O, O—C(O), N—C(O), C(O)—N, O—C(O)—N, N—C(O)—N, O—SO2 or SO2—O, R stands for alkyl having 1 to 4 C atoms, b stands for 0 or 1 and c stands for 0 or 1, q stands for 0 or 1, where at least one radical from b and q stands for 1, and r stands for 0, 1, 2, 3, 4 or 5, to processes for the preparation of these compounds, and to uses of these surface-active compounds.Type: ApplicationFiled: July 2, 2007Publication date: October 22, 2009Applicant: MERCK PATENT GMBHInventors: Wolfgang Hierse, Nikolai (Mykola) Ignatyev, Martin Seidel, Elvira Montenegro, Peer Kirsch, Andreas Bathe
-
Patent number: 7605242Abstract: The invention relates to a process for the depolymerization of glycosaminoglycanes characterized by the use of UVC radiation. The invention also relates to the intermediate depolymerized heparin obtained by the process. The intermediate depolymerized heparin can be dissolved in a buffer solution and fractionated by gel permeation for obtaining the desired molecular weight.Type: GrantFiled: May 6, 2004Date of Patent: October 20, 2009Assignee: Laboratori Derivati Organici S.p.A.Inventors: Luigi De Ambrosi, Donata Bensi, Elena Vismara
-
Publication number: 20090233874Abstract: The present invention is directed to a novel process for the preparation of compounds having inhibitory activity against sodium-dependent glucose transporter (SGLT) being present in the intestine or kidney.Type: ApplicationFiled: September 9, 2008Publication date: September 17, 2009Inventors: Ahmed F. Abdel-Magid, Maureen Chisholm, Steven Mehrman, Lorraine Scott, Kenneth M. Wells, Fan Zhang-Plasket, Sumihiro Nomura, Mitsuya Hongu, Yuichi Koga
-
Publication number: 20090117078Abstract: Described herein are crosslinked compounds useful in numerous treatments. Described herein are methods of making crosslinked compounds via (1) die oxidative coupling of two or more thiol compounds or (2) by the reaction between at least one thiol compound with at least one thiol-reactive compound.Type: ApplicationFiled: October 2, 2008Publication date: May 7, 2009Applicant: University of Utah Research FoundationInventors: Glenn D. Prestwich, Xiao Zheng Shu, Yi Luo, Kelly R. Kirker, Yanchun Liu
-
PROCESS FOR THE PREPARATION OF N-ACYL-(EPI)K5-AMINE-O-SULFATE-DERIVATIVES AND PRODUCTS THUS OBTAINED
Publication number: 20090005341Abstract: A new method is described for the oversulfation of (epi)K5-N-sulfates to obtain (epi)K5-amine-O-oversulfates at extremely high degree of sulfation and for the transformation of these intermediates into new N-acyl-(epi)K5-amine-O-oversulfates basically free of activity on the coagulation parameters and useful in the cosmetic or pharmaceutical field. Also described are pharmaceutical compositions containing, as one of their active ingredients, an (epi)K5-amine-O-oversulfate.Type: ApplicationFiled: May 13, 2008Publication date: January 1, 2009Applicant: GLYCORES 2000 S.R.L.Inventors: Pasqua A. Oreste, Giorgio Zoppetti -
Publication number: 20080299637Abstract: A method of reacting a first chemical entity and a second chemical entity to form a conjugate in which the first and second chemical entities are covalently bound with respect to each other, comprises bringing into simultaneous contact the first chemical entity, the second chemical entity and a thiol generator, wherein the thiol generator reacts with the first chemical entity in a thiolation reaction resulting in formation of a free sulfhydryl group on the first chemical entity, and the free sulfhydryl group reacts with the second chemical entity to form the conjugate, and wherein the second chemical entity is polyvalent with respect to its reactivity with sulfhydryl groups. The present invention primarily differs from the prior art in that no separation step is involved between reaction of the thiol generator and first chemical entity and reaction with the second chemical entity. The invention also provides a conjugation kit.Type: ApplicationFiled: December 12, 2006Publication date: December 4, 2008Inventors: Nicholas Gee, Michael Knowles
-
Publication number: 20080287375Abstract: The invention comprises compounds for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceutical compositions containing the compounds or prodrugs of the compounds. The invention also comprises animal models and methods of making the animal models for studying diseases and disorders related to deficiency or overexpression of O-GlcNAcase, accumulation or deficiency of O-GlcNAc, and treatment of such diseases and disorders. The invention also comprises methods of treating such diseases and disorders. The invention also comprises methods of making the compounds, and methods of making selective glycosidase inhibitors.Type: ApplicationFiled: March 1, 2006Publication date: November 20, 2008Applicant: SIMON FRASER UNIVERSITYInventors: David J. Vocadlo, Garrett Whitworth, Matthew S. Macauley
-
Publication number: 20080139503Abstract: Partially desulphated glycosaminoglycan derivatives are described, particularly heparin, and more particularly a compound of formula (I) where the U, R and R1 groups have the meanings indicated in the description. These glycosaminoglycan derivatives have antiangiogenic and heparanase-inhibiting activity and are devoid of anticoagulant activity.Type: ApplicationFiled: October 31, 2007Publication date: June 12, 2008Applicant: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.p.A.Inventors: Benito Casu, Giangiacomo Torri, Anna Maria Naggi, Giuseppe Giannini, Claudio Pisano, Sergio Penco
-
Patent number: 7202230Abstract: The present invention describes the use of polysaccharide derivatives for the preparation of biocompatible and biodegradable biomaterials with absorbent properties for body fluids and physical hemostatic activity, to be used in both venous and arterial vascular anastomoses to create a physical hemostatic barrier and to prevent scar tissue formation and formation of post-surgical adherence of the vessels to the surrounding tissues.Type: GrantFiled: May 7, 2002Date of Patent: April 10, 2007Assignee: Fidia Advanced Biopolymers, S.R.L.Inventors: Alberto Rivarossa, Daniele Pressato
-
Patent number: 7183261Abstract: Galactosylceramide analogues represented by the following formula (1) or (2). (wherein X and Y each represent S or O, R1 and R2 each represent an alkyl group or an alkenyl group each having 9 to 35 carbon atoms. R3 represents an alkyl group or an alkenyl group each having 2 to 30 carbon atoms.) It is provided a ?-glucocerebrosidase activator which is easily available, and external skin preparations and a method of activating ?-glucocerebrosidase, in which improvement in formation of horny layer transmission barrier is expected by activating ?-glucocerebrosidase so that an improved effect in rough skin is also expected.Type: GrantFiled: June 27, 2002Date of Patent: February 27, 2007Assignee: Kao CorporationInventors: Rie Uematsu, Fumio Nakajima, Masahiro Yoshida, Kyoko Fukunaga, Mariko Hara, Shintaro Inoue, Shinichiro Nishimura